HAYWARD, Calif.--(BUSINESS WIRE)--Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces that the U.S. Patent and Trademark Office has issued US Patent No. 9,138,205 for a Sample Recovery and Collection Device. The issuance of this patent is a first step towards providing efficient and simple to use biosample collection technologies.
“Our corporate mission is to improve human and animal health assessment and research by enabling efficient, cost effective collection, preservation and transportation of biological samples,” said Dr. Bassam El-Fahmawi, President and CTO of Mawi DNA Technologies.
The patent covers the elements used in Mawi’s iSWAB™ technology, an integrated system that combines a unique biosample collection and concentration device with a variety of proprietary buffer formulations. The iSWAB enables room temperature stabilization of DNA, RNA, proteins and oral samples for drug screening. Mawi DNA Technologies’ product development pipeline includes iSWAB-Blood designed to overcome current challenges in Dry Blood Spot collection, as well as a potentially disruptive new formula for stabilizing live, intact cells at ambient conditions for extended time periods.
About Mawi DNA Technologies
Mawi DNA Technologies was founded in 2013 and has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. The company’s flagship product iSWAB-DNA has gained significant market traction due to its ability to be used for animals and all human population segments from infants to the elderly, robust DNA yield and low bacterial DNA content. Mawi DNA Technologies has established relationships with children’s hospitals for neonatal screening and has set up an extensive network of international distributors to market and sell iSWAB products globally. For more information, please visit http://www.mawidna.com.